JINYU(SH:600201) ZHESHANG SECURITIES·2024-06-26 08:02Investment Rating - The investment rating for the company is "Buy" (maintained) [15] Core Insights - The company has received approval from the Shanghai Stock Exchange for a private placement of shares, which will enhance its long-term development capabilities [1][13] - The issuance will optimize the shareholder structure, establishing a solid foundation for sustainable development [2][13] - The company aims to increase its funding strength to support future growth [2][14] Financial Summary - Projected revenue for 2024 is estimated at RMB 1.67 billion, with a growth rate of 4.54% compared to 2023 [5] - The net profit attributable to the parent company is expected to reach RMB 355.9 million in 2024, reflecting a growth of 25.47% [5] - Earnings per share (EPS) is projected to be RMB 0.32 in 2024, with a price-to-earnings (P/E) ratio of 22.70 [5][14] Strategic Development - The company is focusing on enhancing its research and development capabilities across various vaccine platforms to meet the increasing demands of the mature animal health industry [14] - It plans to pursue both organic growth and external acquisitions to strengthen its product offerings and market position [14] - The company is also targeting the growing pet market by developing pet vaccines and related products, which are expected to drive revenue and profit growth [14]